BiologicsMD™ is an early stage therapeutic development company focused on developing highly-targeted or ‘smart’ therapies for the treatment of hair loss diseases and conditions, as well as severe bone disorders.
The company is developing a series of recombinant fusion proteins that provide powerful stimulatory effects directly to the target receptors at the point of disease – and do so with sustained therapeutic exposure in either a single dose or very infrequent dosing regimens.
The company is working on formulation and delivery vehicles that can accommodate parenteral, local, and topical administration.
The company is developing a series of recombinant fusion proteins that provide powerful stimulatory effects directly to the target receptors at the point of disease – and do so with sustained therapeutic exposure in either a single dose or very infrequent dosing regimens.
The company is working on formulation and delivery vehicles that can accommodate parenteral, local, and topical administration.
Location: United States, Arkansas, Fayetteville
Investors 3
| Date | Name | Website |
| - | Connecticu... | ctinnovati... |
| 09.07.2021 | Robin Hood... | robinhoodv... |
| - | VIC Techno... | victech.co... |
Mentions in press and media 8
| Date | Title | Description |
| 29.04.2024 | Wound Care Biologics market valued at USD 8021.6 million by 2029 with a CAGR of 10.2% during 2023-2029 | Wound Care Biologics market valued at USD 8021.6 million by 2029 with a CAGR of 10.2% during 2023-2029 04-29-2024 07:40 PM CET | Health & Medicine Press release from: Quants and Trends Wound Care Biologics market The global Wound Care B... |
| 26.04.2024 | Belgium-based EXO Biologics raises €16M to harness the therapeutic potential of exosomes | Read this article in: Liège-based EXO Biologics, a clinical-stage biotech company, announced on Wednesday, April 24, that it has secured a total of up to €16M in Series A funding. The announcement comes after the company raised €9M from inv... |
| 10.10.2023 | Swiss-based LimmaTech Biologics raises €35M to combat emerging antimicrobial resistance | Read this article in: Zurich-based LimmaTech Biologics AG, a clinical-stage biopharmaceutical company, announced on Monday, October 9, that it has secured $37M (approximately €35M) in a Series A round of funding. The investment was co-led b... |
| 09.10.2023 | LimmaTech Biologics Raises $37M in Series A Funding | LimmaTech Biologics, a Schilieren, Switzerland-based biotech company developing next-generation vaccines to prevent life-threatening diseases, raised $37M in Series A funding. the round was led by Adjuvant Capital, AXA IM Alts, and the Novo... |
| 18.04.2017 | Thirteen new women-led healthcare startups join Springboard’s Health Innovation Hub | “We recently began to tell our story at various Med/Biotech conferences and startup challenges,” explained Singh via email. “We have to approach it judiciously and strategically and, frankly, we need a little guidance on how to navigate our... |
| 29.12.2015 | Qu Biologics Closes CDN$3.5M Financing Round | Qu Biologics Inc., a Vancouver, British Columbia, Canada-based biotechnology company developing Site Specific Immunomodulators (SSIs) that aim to restore the body’s normal immune response, closed an oversubscribed private financing of CDN$3... |
| 09.05.2011 | Cattle Vaccine, Chip Verification Software Take Top Prizes At 2011 Moot Corp. Competition | TNG Pharmaceuticals, developers of a vaccine to keep cattle free of blood-sucking horn flies, took top prize at the “Moot Corp.” business competition this weekend. Formally renamed the Venture Labs Investment Competition(VLIC) in 2010, but ... |
| - | Thirteen new women-led healthcare startups join Springboard’s Health Innovation Hub | A new batch of 13 women-led life science and healthcare startups have been accepted into Springboard Enterprises’ Health Innovation Hub, a year-long program for growth-stage companies preparing to expand and raise funds for new product deve... |